Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions

9Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.

Cite

CITATION STYLE

APA

Dowall, S. D., Graham, V. A., Corbin-Lickfett, K., Empig, C., Schlunegger, K., Bruce, C. B., … Hewson, R. (2015). Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions. Journal of Immunology Research, 2015. https://doi.org/10.1155/2015/347903

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free